|
1
|
Inui A: Cancer anorexia-cachexia syndrome:
Current issues in research and management. CA Cancer J Clin.
52:72–91. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sinno MH, Coquerel Q, Boukhettala N,
Coëffier M, Gallas S, Terashi M, Ibrahim A, Breuillé D, Déchelotte
P and Fetissov SO: Chemotherapy-induced anorexia is accompanied by
activation of brain pathways signaling dehydration. Physiol Behav.
101:639–648. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jahn P, Renz P, Stukenkemper J, Book K,
Kuss O, Jordan K, Horn I, Thoke-Colberg A, Schmoll HJ and
Landenberger M: Reduction of chemotherapy-induced anorexia, nausea
and emesis through a structured nursing intervention: A
cluster-randomized multicenter trial. Support Care Cancer.
17:1543–1552. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Abell TL, Malagelada JR, Lucas AR, Brown
ML, Camilleri M, Go VL, Azpiroz F, Callaway CW, Kao PC, Zinsmeister
AR, et al: Gastric electromechanical and neurohormonal function in
anorexia nervosa. Gastroenterology. 93:958–965. 1987.PubMed/NCBI
|
|
5
|
Bernstein IL and Bernstein ID: Learned
food aversions and cancer anorexia. Cancer Treat Rep. 65(Suppl 5):
S43–S47. 1981.
|
|
6
|
Mantovani G, Macció A, Massa E and Madeddu
C: Managing cancer-related anorexia/cachexia. Drugs. 61:499–514.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Langhans W: Anorexia of infection: Current
prospects. Nutrition. 16:996–1005. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Exton MS: Infection-induced anorexia:
Active host defence strategy. Appetite. 29:369–383. 1997.
View Article : Google Scholar
|
|
9
|
Tohgo A, Kumazawa E, Akahane K, Asakawa A
and Inui A: Anticancer drugs that induce cancer-associated
cachectic syndromes. Expert Rev Anticancer Ther. 2:121–129. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Suárez-Pinilla P, Peña-Pérez C,
Arbaizar-Barrenechea B, Crespo-Facorro B, Del Barrio JA, Treasure J
and Llorca-Díaz J: Inpatient treatment for anorexia nervosa: A
systematic review of randomized controlled trials. J Psychiatr
Pract. 21:49–59. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mondello P, Mian M, Aloisi C, Famá F,
Mondello S and Pitini V: Cancer cachexia syndrome: Pathogenesis,
diagnosis and new therapeutic options. Nutr Cancer. 67:12–26. 2015.
View Article : Google Scholar
|
|
12
|
Brennan AM and Mantzoros CS: Drug Insight:
The role of leptin in human physiology and pathophysiology-emerging
clinical applications. Nat Clin Pract Endocrinol Metab. 2:318–327.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hebebrand J, Muller TD, Holtkamp K and
Herpertz-Dahlmann B: The role of leptin in anorexia nervosa:
Clinical implications. Mol Psychiatry. 12:23–35. 2007. View Article : Google Scholar
|
|
14
|
Eckert ED, Pomeroy C, Raymond N, Kohler
PF, Thuras P and Bowers CY: Leptin in anorexia nervosa. J Clin
Endocrinol Metab. 83:791–795. 1998.PubMed/NCBI
|
|
15
|
Smiechowska J, Utech A, Taffet G, Hayes T,
Marcelli M and Garcia JM: Adipokines in patients with cancer
anorexia and cachexia. J Investig Med. 58:554–559. 2010.PubMed/NCBI
|
|
16
|
Tang CH, Lu DY, Yang RS, Tsai HY, Kao MC,
Fu WM and Chen YF: Leptin-induced IL-6 production is mediated by
leptin receptor, insulin receptor substrate-1, phosphatidylinositol
3-kinase, Akt, NF-kappaB and p300 pathway in microglia. J Immunol.
179:1292–1302. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Trujillo ME, Sullivan S, Harten I,
Schneider SH, Greenberg AS and Fried SK: Interleukin-6 regulates
human adipose tissue lipid metabolism and leptin production in
vitro. J Clin Endocrinol Metab. 89:5577–5582. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Engineer DR and Garcia JM: Leptin in
anorexia and cachexia syndrome. Int J Pept. 2012:2874572012.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Faggioni R, Feingold KR and Grunfeld C:
Leptin regulation of the immune response and the immunodeficiency
of malnutrition. FASEB J. 15:2565–2571. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shirazi R, Palsdottir V, Collander J,
Anesten F, Vogel H, Langlet F, Jaschke A, Schürmann A, Prévot V,
Shao R, et al: Glucagon-like peptide 1 receptor induced suppression
of food intake and body weight is mediated by central IL-1 and
IL-6. Proc Natl Acad Sci USA. 110:16199–16204. 2013. View Article : Google Scholar
|
|
21
|
Hübschle T, Thom E, Watson A, Roth J,
Klaus S and Meyerhof W: Leptin-induced nuclear translocation of
STAT3 immuno-reactivity in hypothalamic nuclei involved in body
weight regulation. J Neurosci. 21:2413–2424. 2001.
|
|
22
|
Priceman SJ, Kujawski M, Shen S,
Cherryholmes GA, Lee H, Zhang C, Kruper L, Mortimer J, Jove R,
Riggs AD and Yu H: Regulation of adipose tissue T cell subsets by
Stat3 is crucial for diet-induced obesity and insulin resistance.
Proc Natl Acad Sci USA. 110:13079–13084. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Borman NH: The history of ancient Korean
medicine. Yonsei Med J. 7:103–118. 1966. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zee-Cheng RK: Shi-quan-da-bu-tang (ten
significant tonic decoction), SQT. A potent Chinese biological
response modifier in cancer immunotherapy, potentiation and
detoxification of anticancer drugs. Methods Find Exp Clin
Pharmacol. 14:725–736. 1992.PubMed/NCBI
|
|
25
|
Saiki I: A Kampo medicine 'Juzen-taiho-to'
prevention of malignant progression and metastasis of tumor cells
and the mechanism of action. Biol Pharm Bull. 23:677–688. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kishida Y, Nishii T, Inoue T, Nishida S,
Arimitsu J, Yoshikawa H and Sugano N: Juzentaihoto (TJ-48), a
traditional Japanese herbal medicine, influences hemoglobin
recovery during preoperative autologous blood donation and after
hip surgery. Int J Clin Pharmacol Ther. 47:716–721. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang CY, Bai XY and Wang CH: Traditional
Chinese medicine: A treasured natural resource of anticancer drug
research and development. Am J Chin Med. 42:543–559. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kin R, Kato S, Kaneto N, Sakurai H,
Hayakawa Y, Li F, Tanaka K, Saiki I and Yokoyama S: Procyanidin C1
from cinnamomi cortex inhibits TGF-β-induced
epithelial-to-mesenchymal transition in the A549 lung cancer cell
line. Int J Oncol. 43:1901–1906. 2013.PubMed/NCBI
|
|
29
|
Matsuda T, Maekawa K, Asano K and
Hisamitsu T: Suppressive effect of juzen-taiho-to on lung
metastasis of b16 melanoma cells in vivo. Evid Based Complement
Alternat Med. 2011:7431532011. View Article : Google Scholar :
|
|
30
|
Choi YK, Jung KY, Woo SM, Yun YJ, Jun CY,
Park JH, Shin YC, Cho SG and Ko SG: Effect of Sipjeondaebo-tang on
cancer-induced anorexia and cachexia in CT-26 tumor-bearing mice.
Mediators Inflamm. 2014:7365632014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Huang SM, Chien LY and Tai CJ, Chiou JF,
Chen CS and Tai CJ: Effectiveness of 3-week intervention of Shi
Quan Da Bu Tang for alleviating hematotoxicity among patients with
breast carcinoma receiving chemotherapy. Integr Cancer Ther.
12:136–144. 2013. View Article : Google Scholar
|
|
32
|
Ogawa K, Omatsu T, Matsumoto C, Tsuchiya
N, Yamamoto M, Naito Y and Yoshikawa T: Protective effect of the
Japanese traditional medicine juzentaihoto on myelosuppression
induced by the anticancer drug TS-1 and identification of a
potential biomarker of this effect. BMC Complement Altern Med.
12:1182012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Sugiyama K, Ueda H and Ichio Y: Protective
effect of juzen-taiho-to against carboplatin-induced toxic side
effects in mice. Biol Pharm Bull. 18:544–548. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Talley RW, O'Bryan RM, Gutterman JU,
Brownlee RW and McCredie KB: Clinical evaluation of toxic effects
of cis-diamminedichloroplatinum (NSC-119875)-phase I clinical
study. Cancer Chemother Rep. 57:465–471. 1973.PubMed/NCBI
|
|
35
|
Safety MOFAD: Guidance on good
manufacturing practices (GMP) for active pharmaceutical
ingredients. 2nd Edition. Korea: 2015
|
|
36
|
World Health Organization: Annex 3
supplementary guidelines on good manufacturing practices for the
manufacture of herbal medicines. (WHO Technical Report Series). pp.
85–106. 2006
|
|
37
|
Center for Drug Evaluation and Research
PQMSC: Pharmaceutical components at risk for melamine contamination
services. Dohah US: 1992
|
|
38
|
Higby DJ, Wallace HJ Jr and Holland JF:
Cis-diamminedichloroplatinum (NSC-119875): A phase I study. Cancer
Chemother Rep. 57:459–463. 1973.PubMed/NCBI
|
|
39
|
Poth KJ, Guminski AD, Thomas GP, Leo PJ,
Jabbar IA and Saunders NA: Cisplatin treatment induces a transient
increase in tumorigenic potential associated with high
interleukin-6 expression in head and neck squamous cell carcinoma.
Mol Cancer Ther. 9:2430–2439. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Fantuzzi G and Faggioni R: Leptin in the
regulation of immunity, inflammation and hematopoiesis. J Leukoc
Biol. 68:437–446. 2000.PubMed/NCBI
|
|
41
|
Sugiyama K, Ueda H, Ichio Y and Yokota M:
Improvement of cisplatin toxicity and lethality by juzen-taiho-to
in mice. Biol Pharm Bull. 18:53–58. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Suh SY, Choi YS, Yeom CH, Kwak SM, Yoon
HM, Kim DG, Koh SJ, Park J, Lee MA, Lee YJ, et al: Interleukin-6
but not tumour necrosis factor-alpha predicts survival in patients
with advanced cancer. Supportive Care Cancer. 21:3071–3077. 2013.
View Article : Google Scholar
|
|
43
|
Wang SW and Sun YM: The IL-6/JAK/STAT3
pathway: Potential therapeutic strategies in treating colorectal
cancer (Review). Int J Oncol. 44:1032–1040. 2014.PubMed/NCBI
|
|
44
|
Huang WL, Yeh HH, Lin CC, Lai WW, Chang
JY, Chang WT and Su WC: Signal transducer and activator of
transcription 3 activation up-regulates interleukin-6 autocrine
production: A biochemical and genetic study of established cancer
cell lines and clinical isolated human cancer cells. Mol Cancer.
9:3092010. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Saiki I, Yamaura T, Ohnishi Y, Hayakawa Y,
Komatsu Y and Nunome S: HPLC analysis of juzen-taiho-to and its
variant formulations and their antimetastatic efficacies. Chem
Pharm Bull (Tokyo). 47:1170–1174. 1999. View Article : Google Scholar
|
